The glycan carbohydrate antigen 19-9 (CA19-9), also known as sialic acid-Lewis^A, plays a crucial role in the process of intercellular recognition. Due to the high sensitivity and specificity of CA19-9 for pancreatic cancer, CD BioGlyco provides glyco-biomarker CA19-9 detection service through various methods to help researchers explore new therapies for pancreatic cancer.

CA19-9

Pancreatic ductal adenocarcinoma is the leading cause of cancer-related death and has the lowest survival rate of any solid cancer. The discovery of biomarkers for early detection of pancreatic cancer is an urgent need to improve survival, although studies evaluating biomarkers for early detection are rarely performed using samples from patients with the preclinical disease. It has been reported that CA19-9 is one of the most important and widely used glyco-biomarkers for pancreatic cancer.

CA19-9 can be used as an adjuvant diagnostic indicator for pancreatic cancer, gallbladder cancer and other malignancies. This antigen exists in the pancreatic, gallbladder, liver and intestinal tissues of embryonic fetuses, and the content in normal human tissues is very low. In the serum of patients with malignant tumors of the digestive tract, especially pancreatic cancer and gallbladder cancer, the content of CA 19-9 is significantly increased. But it is mainly used as an indicator for disease monitoring and predicting recurrence rather than early diagnosis. In addition, CA19-9 is useful for the differential diagnosis of gastrointestinal diseases (e.g. pancreatic cancer and pancreatitis, gastric cancer and gastric ulcer).

Learn More About CA19-9 and Advance Your Glycobiology Research

The exceptional accuracy and detail of CD BioGlyco's glyco-biomarker CA19-9 detection service are powered by an integration of sophisticated analytical technologies.

• Our primary methodology involves high-performance liquid chromatography (HPLC) coupled with mass spectrometry (MS). This powerful combination allows for the precise separation of complex CA19-9 glycoforms and their subsequent identification and quantification with unparalleled sensitivity.
• We employ lectin microarray analysis, a high-throughput method that utilizes a diverse array of lectins to rapidly profile changes in CA19-9 glycosylation patterns.
• For specific glycoform epitopes, we use customized enzyme-linked immunosorbent assays (ELISAs) for preliminary screening and validation of results.
• Our company uses protein microarrays based on near-infrared plasma gold nanostructures to provide CA 19-9 services to clients. This method allows for nanoscale control of plasma substrate structures through colloidal lithography, thereby improving sensitivity and adjustability.
• We use a simple method involving an enzyme-free colorimetric immunosensor based on magnetic iron oxide-coated gold nanorods (MGNR) nanocomposites to provide CA19-9 detection. This method is sensitive, cost-effective, and specific for detecting CA19-9, enabling pancreatic cancer risk assessment using a small amount of serum without the need for any enhancement solutions or enzymes.

Workflow

Applications

• Our professional CA19-9 testing services can be used to develop new biosensors and diagnostic tools.
• Our CA19-9 testing service can be used to study its role in the tumor microenvironment and immune response.
• Our professional CA19-9 testing service can be used to identify novel glyco-biomarkers associated with various gastrointestinal malignancies and inflammatory diseases.
• Our professional CA19-9 testing service can be used to evaluate the effects of new drugs on the glycosylation pathway and CA19-9 glycoform expression.

Advantages of Us

• We provide both qualitative identification of novel CA19-9 glyco-signatures and precise quantitative analysis of known glycoforms.
• Our service is highly adaptable to diverse sample matrices, including human serum, plasma, pancreatic cyst fluid, and tissue homogenates.
• We are equipped to manage projects of varying scales, from small pilot studies to extensive cohort analyses, always delivering tailored solutions to meet specific research demands.
• By combining advanced HPLC-MS with lectin microarray technologies, we achieve unparalleled specificity in discerning subtle glycoform variations and superior resolution for comprehensive CA19-9 glycoprofiling.

Publication Data

Frequently Asked Questions

CD BioGlyco is dedicated to detecting a range of biomarkers including CA19-9 for early cancer diagnosis in small sample sizes, and we offer a wide range of services to meet your research needs. If you are interested in our services, please feel free to contact us.

Associated Services